News from biolinerx ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 04, 2019, 07:00 ET BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and...


Dec 11, 2018, 07:00 ET BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the...


Nov 01, 2018, 08:00 ET BioLineRx to Report Third Quarter 2018 Results on November 8, 2018

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will...


May 22, 2018, 07:00 ET BioLineRx Reports First Quarter 2018 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its...


Jan 17, 2018, 07:00 ET BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial...


Dec 05, 2017, 07:45 ET BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY

BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast...


Nov 21, 2017, 06:00 ET BioLineRx Reports Third Quarter 2017 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial...


Sep 07, 2017, 08:00 ET BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its...


Aug 08, 2017, 07:00 ET BioLineRx Reports Second Quarter 2017 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial...


Aug 02, 2017, 07:00 ET BioLineRx to Report Second Quarter 2017 Results on August 8, 2017

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it...


Aug 11, 2016, 07:15 ET BioLineRx Reports Second Quarter 2016 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising ...


May 19, 2016, 07:00 ET BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences

BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological...


May 17, 2016, 08:04 ET BioLineRx Reports First Quarter 2016 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Mar 23, 2016, 07:00 ET BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and...


Mar 03, 2016, 07:00 ET BioLineRx to Report Annual 2015 Results on March 10, 2016

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Feb 01, 2016, 07:00 ET BioLineRx to Present at 2016 BIO CEO & Investor Conference in New York on February 8

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...


Jan 25, 2016, 07:00 ET BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Jan 12, 2016, 07:00 ET BioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study...


Jan 04, 2016, 07:00 ET BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...